Venous Thrombosis  >>  rivaroxaban  >>  Phase 2
Welcome,         Profile    Billing    Logout  

9 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
rivaroxaban / Generic mfg.
ODIXa-HIP2, NCT00398905: Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement

Completed
2
726
Europe, RoW
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin
Bayer
Venous Thromboembolism
 
09/04
NCT00402467: An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study

Completed
2
613
US, Canada
Rivaroxaban (BAY59-7939), Rivaroxaban, (BAY59-7939), Enoxaparine
Bayer
Venous Thromboembolism
11/04
11/04
ODIXaHIP-OD, NCT00396786 / 2004-001341-14: Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement

Completed
2
877
Europe, RoW
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin
Bayer
Venous Thromboembolism
07/05
07/05
NCT00839163 / 2004-001083-43: Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)

Completed
2
613
Europe, Canada, RoW
Xarelto (Rivaroxaban, BAY59-7939), Enoxaparin/Vitamin K-Antagonist
Bayer
Venous Thrombosis, Deep Vein Thrombosis
10/05
10/05
NCT00395772 / 2004-002171-16: Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis

Completed
2
543
US, Canada, Europe, RoW
Xarelto (Rivaroxaban, BAY59-7939), (LMW) Heparin + Vitamin K Antagonist
Bayer, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Venous Thromboembolism
 
12/05
NCT00786422 / 2008-003303-31: Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer

Completed
2
25
Europe, RoW
Rivaroxaban (Xarelto, BAY59-7939)
Bayer, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Venous Thrombosis, Deep Vein Thrombosis
05/11
06/11
NCT02271399: Comparative Study of Prophylactic Agent for Venous Thromboembolism After Total Knee Arthroplasty

Completed
2
156
RoW
acetylsalicylic acid, Aspirin(Bayer), rivaroxaban, xarelto(bayer)
Hanyang University Seoul Hospital
Venous Thromboembolism
01/16
02/16
EINSTEINJunior, NCT01684423 / 2011-004539-30: Oral Rivaroxaban in Children With Venous Thrombosis

Completed
2
64
US, Canada, Europe, RoW
Rivaroxaban (Xarelto, BAY59-7939), Active comparator, Rivaroxaban (BAY59-7939) suspension
Bayer, Janssen Research & Development, LLC
Venous Thrombosis
09/16
09/16
EINSTEINJr, NCT02309411 / 2014-000566-22: EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis

Completed
2
46
Canada, Japan, US, Europe, RoW
Rivaroxaban (Xarelto, BAY59-7939)
Bayer, Janssen Research & Development, LLC
Venous Thromboembolism
04/17
04/17

Download Options